Hľadáte kvalitu ? Hľadáte nás !

karuna therapeutics news

View More Events. BidaskClub lowered Karuna Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 10th. Following the completion of the sale, the chief operating officer now owns 45,500 shares in the company, valued at approximately $4,314,310. A number of large investors have recently modified their holdings of the stock. Terms of Use. The big Karuna Therapeutics news is that the study for using KarXT to treat acute psychosis in patients with schizophrenia was a success. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The shares were sold at an average price of $94.82, for a total value of $474,100.00. Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX) May. On December 22, 2020, the board of directors (the "Board") of Karuna Therapeutics, Inc. (the "Company") appointed Denice Torres as a member of the Company's Board, effective immediately. ET on Zacks.com. Latest Share Price and Events. Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring. View the latest news on KRTX company insiders for their impact on company performance. View More News. News and research before you hear about it on CNBC and others. “We hoped to bring a different treatment profile than what was … The business’s 50 day simple moving average is $96.08 and its 200 day simple moving average is $89.43. salesforce.com (NYSE:CRM) Earns “Buy” Rating from The Goldman Sachs Group » NEXT. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. In other Karuna Therapeutics news, Director Atul Pande sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 12th. Recent News. Nebula Holdings Llc Sells … « PREVIOUS. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Several analysts have issued reports on KRTX shares. Free forex prices, toplists, indices and lots more. View the latest news on KRTX company insiders for their impact on company performance. Why Karuna Therapeutics Stock Is Skyrocketing Today. Sofinnova Investments Inc. now owns 1,952,441 shares of the company’s stock worth $150,963,000 after buying an additional 66,839 shares in the last quarter. Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial. Featured Story: Find a Trading Strategy That Works. Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. ET on Zacks.com. Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Includes articles, videos and real-time news from StockTwits. « PREVIOUS. Committed to transform the lives of people living with serious neuropsychiatric disorders. How has Karuna Therapeutics's share price performed over time and what events caused price changes? Time (ET) MT Newswires. Two investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Karuna Therapeutics (NASDAQ:KRTX) COO Andrew Craig Miller sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 10th. Karuna Therapeutics Inc. individual insider activity by MarketWatch. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX) May. Andrew Miller, the company’s founder and chief operating officer, spoke with BioSpace about the company and recent financing and research news. BlackRock Inc. boosted its holdings in shares of Karuna Therapeutics by 2.2% in the 3rd quarter. BOSTON --(BUSINESS WIRE)--Aug. 13, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, On track to initiate Phase 3 trials within the EMERGENT program, the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia, by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected by the end of 2020 Plans to, Topline results of exploratory trial do not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers The Company will not move forward to evaluate KarXT for the treatment of pain The safety and tolerability profile of KarXT was consistent, BOSTON --(BUSINESS WIRE)--Jul. Why Karuna Therapeutics Stock Is Skyrocketing Today. Ms. Torres will serve as a Class III director, to serve until … Upcoming Events. Watchlist; Kurse ; Charts; Trades; News; Fundamental; Toplisten; … Claim your 1-week free trial to StreetInsider Premium here. 13/10/2020 21:38:33 +44 (0) 203 8794 460 Free Membership Login. The Motley Fool - 1 year ago. Daily Ratings & News for Karuna Therapeutics Complete the form below to receive the latest headlines and analysts' recommendations for Karuna Therapeutics with our free daily email newsletter: Follow @DakotaFinancial. Andrew Miller, the company’s founder and chief operating officer, spoke with BioSpace about the company and recent financing and research news. « PREVIOUS. Karuna Therapeutics' new approach to treating schizophrenia delivered positive results in a mid-stage trial. Karuna Therapeutics Inc. individual insider activity by MarketWatch. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended September 30, … The shares were sold at an average price of $78.67, for a total value of $393,350.00. Purchases 1,200,232 Shares of Atlantica Sustainable Infrastructure plc (NASDAQ:AY) » NEXT. (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with … 30, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and. The shares were sold at an average price of $96.84, for a total value of $484,200.00. Company profile page for Karuna Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information 20, 2020 at 8:48 a.m. Dec 22, 2020 11:34 UTC. BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors Zacks Investment Research lowered Karuna Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 6th. BlackRock Inc. Print Page Email Page RSS Feeds Email Alerts Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology … Karuna is on a mission to develop first-in-class therapeutics with the potential to transform the lives of people with serious neuropsychiatric disorders Altering the story of serious mental illness There are no upcoming events available at this time. Sofinnova Investments Inc. grew its position in Karuna Therapeutics by 3.5% during the third quarter. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. All Rights Reserved.Privacy Policy. BlackRock Inc. boosted its stake in shares of Karuna Therapeutics (NASDAQ:KRTX) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Kevin R. Thornal Sells 16,869 Shares of Hologic, Inc. (NASDAQ:HOLX) Stock, Nebula Holdings Llc Sells 4,413,671 Shares of Open Lending Co. (NASDAQ:LPRO) Stock, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? New Strong Buy Stocks for May 13th May. 05/28 10:21. Business Wire. Stock Advisor Flagship service. Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Also, CFO Troy A. Ignelzi sold 564 shares of the company’s stock in a transaction dated Friday, November 6th. Earnings for Karuna Therapeutics are expected to decrease in the coming year, from ($2.56) to ($3.74) per share. Karuna Therapeutics (KRTX) share price, charts, trades & the UK's most popular discussion forums. Finally, State Street Corp boosted its holdings in shares of Karuna Therapeutics by 5.0% in the 3rd quarter. Maxim Group started coverage on Karuna Therapeutics in a research note on Thursday, November 19th. Finally, ValuEngine upgraded Karuna Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 20th. Karuna Therapeutics believes it can preferentially target and stimulate muscarinic receptors in the central nervous system, and leave those in the peripheral tissues unaffected. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Ms. Torres will serve as a Class III director, to serve until the Company's annual meeting of stockholders in 2022. Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development. Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting www.businesswire.com - May 27 at 6:50 AM: Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX) In other Karuna Therapeutics news, Director Heather Preston purchased 350 shares of the firm’s stock in a transaction dated Friday, September 4th. The Motley Fool - 1 year ago. The stock currently has a consensus rating of “Buy” and a consensus target price of $130.20. Karuna Therapeutics, Inc. … Andrew Craig Miller also recently made the following trade(s): Shares of NASDAQ:KRTX opened at $98.57 on Wednesday. Karuna Therapeutics News. BOSTON --(BUSINESS WIRE)--Dec. 22, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, Ed Harrigan , M.D., to step down from Karuna’s board and continue to serve on the Company’s scientific advisory board BOSTON --(BUSINESS WIRE)--Dec. 3, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies. Vanguard Group Inc. boosted its holdings in shares of Karuna Therapeutics by 116.6% in the 2nd quarter. 20, 2020 at 8:48 a.m. The shares were sold at an average price of $94.82, for a total value of $474,100.00. FIL Ltd now owns 899,227 shares of the company’s stock valued at $100,228,000 after purchasing an additional 278,715 shares in the last quarter. The P/E ratio of Karuna Therapeutics is -52.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Karuna Therapeutics CEO Dr. Steve Paul told CNBC on Friday that the biotech firm is hopeful its new therapy for schizophrenia will prove effective for patients in … Why Karuna Therapeutics Stock Is Skyrocketing Today. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to Market Watch - 1 year ago. document.write((new Date()).getFullYear()); On December 22, 2020, the board of directors (the "Board") of Karuna Therapeutics, Inc. (the "Company") appointed Denice Torres as a member of the Company's Board, effective immediately. SINA (NASDAQ:SINA) … Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. Karuna Therapeutics believes it can preferentially target and stimulate muscarinic receptors in the central nervous system, and leave those in the peripheral tissues unaffected. View the real-time KRTX price chart on Robinhood and decide if you want to buy or sell commission-free. New Strong Buy Stocks for May 13th May. Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates BOSTON & PARAMUS, N.J. --(BUSINESS WIRE)--Jul. Karuna Therapeutics. BlackRock Inc. now owns 1,287,558 shares of the company’s stock valued at $99,554,000 after purchasing an additional 27,853 shares in the last quarter. Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Get the latest news and breaking stories for Karuna Therapeutics (KRTX) stock. S&P. They issued a “buy” rating and a $150.00 price objective on the stock. Get today's Karuna Therapeutics Inc stock price and latest KRTX news as well as Karuna Therapeutics real-time stock quotes, technical analysis, full financials and more. The firm owned 1,287,558 shares of the company’s stock after buying an additional 27,853 shares during the quarter. APStock B oston-based biotech Karuna Therapeutics (KRTX) said Monday that a novel combination pill achieved the main goal of a mid-stage clinical trial … Find the latest news headlines from Karuna Therapeutics, Inc. Common Stock (KRTX) at Nasdaq.com. Sell-side analysts predict that Karuna Therapeutics will post -2.56 EPS for the current fiscal year. Get today's Karuna Therapeutics Inc stock price and latest KRTX news as well as Karuna Therapeutics real-time stock quotes, technical analysis, full financials and more. Karuna Therapeutics (NASDAQ:KRTX) COO Andrew Craig Miller sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 10th. Why Karuna Therapeutics Stock Is Soaring Again Today The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock. State Street Corp now owns 799,636 shares of the company’s stock valued at $61,828,000 after purchasing an additional 38,290 shares in the last quarter. Karuna Therapeutics Q3 EPS $(0.71) Down From $(0.39) YoY Benzinga Newsdesk Thu, 05 Nov 2020 06:15:07 -0500 Overview Of Value Stocks In The Healthcare Sector Benzinga Insights Mon, 26 … Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. The stock was bought at … BlackRock Inc. owned 4.84% of Karuna […] Wire. Volatility Over Time: KRTX's weekly volatility (7%) has been stable over the past year. On Monday, October 12th, Andrew Craig Miller sold 5,000 shares of Karuna Therapeutics stock. Analyst Actions: HC Wainwright Starts Karuna Therapeutics at Buy With $140 Price Target. Following the completion of the sale, the chief operating officer now owns 45,500 shares in the […] Real time Karuna Therapeutics Inc (KRTX) stock price quote, stock graph, news & analysis. Return. Latest Stock Picks Investing Basics Premium Services. This saw it … //-->